Produits et services

Promotion and advertising services for pharmaceutical and health care products

Abrégé

The present invention relates to an inhalable pharmaceutical composition for treating asthma, containing salbutamol as the active ingredient, and also containing excipients such as a surfactant, an isosmotic agent, a diluent, a viscosity enhancer, a preservative and a pH adjusting agent.

Classes IPC  ?

• A61K 9/72 - Préparations médicinales caractérisées par un aspect particulier à fumer ou inhaler
• A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
• A61P 11/06 - Antiasthmatiques

Abrégé

Parenteral pharmaceutical formulation or composition, in suspension, having sustained release, containing suspended particles of estradiol and progesterone for hormonal replacement in female mammals in low and ultralow dosage; the formulation consists of an injectable suspension comprising particles of estradiol, particles of progesterone, a surfactant agent, an isosmotic agent, a thickening agent, and one or more preservation agents, wherein the estradiol is in particles having a size between 1 and 100 microns and the progesterone is in particles having a size between 1 and 100 microns, for application thereof in parenteral, intramuscular, subcutaneous or intradermal pharmaceutical form.

Classes IPC  ?

• A61K 31/565 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol
• A61K 31/57 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone
• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61P 5/30 - Œstrogènes
• A61P 5/34 - Progestatifs

Abrégé

The present invention concerns a compound for treating or preventing a pulmonary disease, the compound having the following formula: N-sulphoethylnicotinamide (NESA, [N-nicotinamide] - ethanesulphonic acid 2) and the pharmaceutically acceptable derivatives thereof. In a preferred embodiment of the invention a pharmaceutical composition comprises the compound N-sulphoethylnicotinamide (NESA) or a pharmaceutically acceptable derivative thereof. The purpose of the composition is to treat or prevent a pulmonary disease. In particular, the composition comprises between approximately 7 mg and approximately 1 g of N-sulphoethylnicotinamide (NESA) or a pharmaceutically acceptable derivative thereof. Preferably, the composition comprises between approximately 140 mg and approximately 800 mg of N-sulphoethylnicotinamide (NESA) or a pharmaceutically acceptable derivative thereof. More preferably, the composition comprises between approximately 250 mg and approximately 500 mg of N-sulphoethylnicotinamide (NESA) or a pharmaceutically acceptable derivative thereof.

Classes IPC  ?

• C07D 213/82 - AmidesImides en position 3
• A61K 31/4406 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 3, p. ex. zimeldine
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

The present invention refers to a novel compound which inhibits, avoids or prevents unwanted formation of fibrous tissue which has the following structural formula: N-sulphoethylnicotinamide (NESA, ethanesulphonic acid 2 - [N-nicotinamide]) and the pharmaceutically acceptable derivatives thereof. In one particular embodiment of the invention a pharmaceutical composition which comprises the compound N-sulphoethylnicotinamide (NESA) or a pharmaceutically acceptable derivative thereof. In accordance with the present invention, the pharmaceutical composition which includes NESA can be administered by any of the following means: oral, inhalatory, intranasal, parenteral, intrarectal, intravenous, intramuscular, subcutaneous, intrathecal, intra-articular, transcoelomic, intralesional and percutaneous.

Classes IPC  ?

• C07D 213/82 - AmidesImides en position 3
• A61K 31/4406 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 3, p. ex. zimeldine
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

The present invention concerns a method for preparing a salt of ethanesulphonic acid 2-[N-nicotinamide] comprising at least one step wherein the triethylammonium salt of ethanesulphonic acid 2-[N-nicotinamide] is obtained. A specific embodiment of the invention is a method for preparing the triethylammonium salt of ethanesulphonic acid 2-[N-nicotinamide] which involves obtaining the mixed anhydride of nicotinic acid and alkyl chloroformiate, and making said mixed anhydride react with taurine in the presence of triethylamine.

Classes IPC  ?

• C07D 213/82 - AmidesImides en position 3
• C07C 309/15 - Acides sulfoniques ayant des groupes sulfo liés à des atomes de carbone acycliques d'un squelette carboné acyclique saturé contenant des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso, liés au squelette carboné contenant des groupes amino liés au squelette carboné l'atome d'azote d'au moins un des groupes amino faisant partie de l'un des groupes X étant un hétéro-atome, Y étant un atome quelconque
• C07C 303/32 - Préparation d'esters ou d'amides d'acides sulfuriquesPréparation d'acides sulfoniques ou de leurs esters, halogénures, anhydrides ou amides de sels d'acides sulfoniques